Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, Buzaid A, Robertson C, Shenaq S, Curling P, Burke T, Ericsson C
University of Texas M.D. Anderson Cancer Center, Houston, USA.
Ann Intern Med. 1997 Aug 15;127(4):267-74. doi: 10.7326/0003-4819-127-4-199708150-00002.
Central venous catheters are a principal source of nosocomial bloodstream infections, which are difficult to control.
To determine the efficacy of catheters coated with minocycline and rifampin in preventing catheter-related colonization and bloodstream infections.
Multicenter, randomized clinical trial.
Five university-based medical centers.
281 hospitalized patients who required 298 triple-lumen, polyurethane venous catheters.
147 catheters were pretreated with tridodecylmethyl-ammonium chloride and coated with minocycline and rifampin. Untreated, uncoated catheters (n = 151) were used as controls.
Quantitative catheter cultures, blood cultures, and molecular typing of organisms to determine catheter-related colonization and bloodstream infections.
The group with coated catheters and the group with uncoated catheters were similar with respect to age, sex, underlying diseases, degree of immunosuppression, therapeutic interventions, and risk factors for catheter infections. Colonization occurred in 36 (26%) uncoated catheters and 11 (8%) coated catheters (P < 0.001). Catheter-related bloodstream infection developed in 7 patients (5%) with uncoated catheters and no patients with coated catheters (P < 0.01). Multivariate logistic regression analysis showed that coating catheters with minocycline and rifampin was an independent protective factor against catheter-related colonization (P < 0.05). No adverse effects related to the coated catheters or antimicrobial resistance were seen. An estimate showed that the use of coated catheters could save costs.
Central venous catheters coated with minocycline and rifampin can significantly reduce the risk for catheter-related colonization and bloodstream infections. The use of these catheters may save costs.
中心静脉导管是医院血流感染的主要来源,难以控制。
确定米诺环素和利福平涂层导管预防导管相关定植和血流感染的效果。
多中心随机临床试验。
五所大学附属医院。
281例住院患者,需要298根三腔聚氨酯静脉导管。
147根导管用三甲基十二烷基氯化铵预处理,并涂有米诺环素和利福平。未处理、未涂层的导管(n = 151)用作对照。
导管定量培养、血培养和微生物分子分型,以确定导管相关定植和血流感染。
涂层导管组和未涂层导管组在年龄、性别及基础疾病、免疫抑制程度、治疗干预措施和导管感染危险因素方面相似。36根(26%)未涂层导管发生定植,11根(8%)涂层导管发生定植(P < 0.001)。7例(5%)使用未涂层导管的患者发生导管相关血流感染,使用涂层导管的患者无感染发生(P < 0.01)。多因素logistic回归分析显示,米诺环素和利福平涂层导管是预防导管相关定植的独立保护因素(P < 0.05)。未观察到与涂层导管相关的不良反应或耐药性。一项评估显示,使用涂层导管可节省成本。
米诺环素和利福平涂层中心静脉导管可显著降低导管相关定植和血流感染风险。使用这些导管可能节省成本。